At Emergent, we’re ready to be that CDMO partner for you. We have foundational expertise in live viral development and manufacturing, among our other core competencies. And we invest heavily in the tools and know-how to deliver on the promise of emerging viral platforms.
Today, for example, that investment has extended into new capabilities at our Rockville, Maryland site. Our current isolator line features integrated BSL2 containment through parts preparation, filling, lyophilization, capping, and exterior vial decontamination. Those capabilities have been augmented through the addition of a second BSL2 line, the INTEGRA, with the same end-to-end functions and:
- High-speed fill/finish operations
- Eight-headed filler (maximum speed of 234 vpm)
- Automated stoppering fed from vibratory bowl
- Vial sizes: 2R to 100R
- Automated 100% IPC
- Liquid filling (available Q1 2023)
- Lyophilization with auto-load (anticipated to be available in 2023)
